Early-stage malignant neoplasm of the commissure of lip — classified as T1 or T2 lip cancer — is a localised disease with well-defined treatment pathways. This page summarises the clinical scenario and offers a partial overview of the approach; the complete structured protocol is one click away.
T1 and T2 stage lip cancer represents localised, early-stage disease. Five-year crude survival rates for surgically treated T1–T2 tumours are substantially higher than for advanced disease. Early stage cancer can be treated equally well by surgery or radiation therapy, giving clinicians and patients a meaningful choice of modality.
Management centres on a choice between surgical excision and radiation-based modalities — including external beam radiotherapy and brachytherapy — with photodynamic therapy available in selected cases. The specific modality selection, sequencing, and all other protocol details are in the full regimen below.
DOI: 10.1017/S0022215116000499
The five-year crude survival rates for surgical treatment are about 75–80 per cent for T1 to T2 tumours, dropping to 40–50 per cent for T3 and T4 tumours.
Early stage cancer can be treated equally well by surgery or radiation therapy.
Small lesions are managed by simple surgical excision and primary closure.
Equally good results can be achieved with fractionated EBRT or brachytherapy.
Foscan® mediated PDT can also be used to treat primary cancer of the lip, where treatment yields complete response rates comparable with those published for surgery or RT.
View source ↗